Phase I-II first-in-human clinical study of intraputamenal CDNF in Parkinson’s disease: Exploratory PET imaging endpoints of the 12-month treatment period
Objective: To test if intermittent intraputamenal monthly infusions of CDNF have an effect on striatal dopamine transporter (DAT) binding, as measured by PET, in subjects…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Clinical research of serum uric acid levels in Parkinson’s disease
Objective: To analyzed the variation of uric acid (UA) traits in different Hoehn-Yahr staging in Parkinson's disease (PD). Background: PD is a common neurodegenerative disease.…Anti-parkinson effect of natural L-DOPA containing drug Mucuna pruriens against the rotenone induced rat model of Parkinson’s disease
Objective: The nanoherbaceutical formulation comprising natural L-DOPA from Mucuna pruriens against rotenone caused Parkinson's disease in rats to be prepared and evaluated. Background: Parkinson's disease…Effects of a next-generation neurotrophic compound in a toxin model of Parkinson’s disease
Objective: Investigate the effects of a peripherally administered novel neurotrophic compound, CMx01a, in 6-hydroxydopamine rat model of Parkinson’s disease. Background: Neurotrophic factors are promising drug…Creating National Competencies in Physical Activity for Exercise Professionals Working with People with Parkinson’s Disease
Objective: On March 5-6th 2020, the Parkinson’s Foundation is convening a meeting to assemble thought leaders in physical activity and education for Parkinson’s disease. Our…Thiazolidinedione use is associated with reduced risk of Parkinson’s disease in patients with diabetes
Objective: This meta-analysis is aimed to explore the association between thiazolidinedione (TZD) use and Parkinson’s disease (PD) risk. Background: Recent epidemiological studies found protective effects of TZD class of drugs in…Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study
Objective: This study aims to identify the reasons why people living with Parkinson’s disease (PD) (PwP) became involved with the PD STAT randomised controlled trial…Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?
Objective: Design an early CT program to detect a neuroprotective signal in PD. Background: Attempts to develop PD modifying therapies have been largely disappointing so…Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study
Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 15
- Next Page »